Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imlifidase vs plasmapheresis for active antibody-mediated rejection in kidney transplant patients
2018-000022-66Phase 2Completed
- Sponsor
- Hansa Biopharma
- Start
- Dec 2018
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of imlifidase in Antibody-mediated kidney allograft rejection (AMR) and kidney allograft rejection (2 arms), sponsored by Hansa Biopharma. Primary endpoint: Maximum reduction in mean DSA level within 5 days. Started Dec 2018; status: completed.
02
Drugs
imlifidase
03
Conditions
Antibody-mediated kidney allograft rejection (AMR)kidney allograft rejection
Beyond the preview
Go deeper on 2018-000022-66.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000022-66.